586 related articles for article (PubMed ID: 15936217)
1. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation.
Guo L; Guthrie H
J Pharmacol Toxicol Methods; 2005; 52(1):123-35. PubMed ID: 15936217
[TBL] [Abstract][Full Text] [Related]
2. Improved throughput of PatchXpress hERG assay using intracellular potassium fluoride.
Zeng H; Penniman JR; Kinose F; Kim D; Trepakova ES; Malik MG; Dech SJ; Balasubramanian B; Salata JJ
Assay Drug Dev Technol; 2008 Apr; 6(2):235-41. PubMed ID: 18471077
[TBL] [Abstract][Full Text] [Related]
3. Application of PatchXpress planar patch clamp technology to the screening of new drug candidates for cardiac KCNQ1/KCNE1 (I Ks) activity.
Trepakova ES; Malik MG; Imredy JP; Penniman JR; Dech SJ; Salata JJ
Assay Drug Dev Technol; 2007 Oct; 5(5):617-27. PubMed ID: 17939752
[TBL] [Abstract][Full Text] [Related]
4. A place for high-throughput electrophysiology in cardiac safety: screening hERG cell lines and novel compounds with the ion works HTTM system.
Guthrie H; Livingston FS; Gubler U; Garippa R
J Biomol Screen; 2005 Dec; 10(8):832-40. PubMed ID: 16234341
[TBL] [Abstract][Full Text] [Related]
5. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
[TBL] [Abstract][Full Text] [Related]
6. Early evaluation of compound QT prolongation effects: a predictive 384-well fluorescence polarization binding assay for measuring hERG blockade.
Deacon M; Singleton D; Szalkai N; Pasieczny R; Peacock C; Price D; Boyd J; Boyd H; Steidl-Nichols JV; Williams C
J Pharmacol Toxicol Methods; 2007; 55(3):238-47. PubMed ID: 17141530
[TBL] [Abstract][Full Text] [Related]
7. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
[TBL] [Abstract][Full Text] [Related]
8. HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk.
Wible BA; Hawryluk P; Ficker E; Kuryshev YA; Kirsch G; Brown AM
J Pharmacol Toxicol Methods; 2005; 52(1):136-45. PubMed ID: 15950494
[TBL] [Abstract][Full Text] [Related]
9. Blockade of the I(Ks) potassium channel: an overlooked cardiovascular liability in drug safety screening?
Towart R; Linders JT; Hermans AN; Rohrbacher J; van der Linde HJ; Ercken M; Cik M; Roevens P; Teisman A; Gallacher DJ
J Pharmacol Toxicol Methods; 2009; 60(1):1-10. PubMed ID: 19439185
[TBL] [Abstract][Full Text] [Related]
10. QT interval prolongation and cardiac risk assessment for novel drugs.
Picard S; Lacroix P
Curr Opin Investig Drugs; 2003 Mar; 4(3):303-8. PubMed ID: 12735231
[TBL] [Abstract][Full Text] [Related]
11. The hERG potassium channel and hERG screening for drug-induced torsades de pointes.
Hancox JC; McPate MJ; El Harchi A; Zhang YH
Pharmacol Ther; 2008 Aug; 119(2):118-32. PubMed ID: 18616963
[TBL] [Abstract][Full Text] [Related]
12. Estimation of potency of HERG channel blockers: impact of voltage protocol and temperature.
Yao JA; Du X; Lu D; Baker RL; Daharsh E; Atterson P
J Pharmacol Toxicol Methods; 2005; 52(1):146-53. PubMed ID: 15936218
[TBL] [Abstract][Full Text] [Related]
13. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
Lawrence CL; Pollard CE; Hammond TG; Valentin JP
J Pharmacol Toxicol Methods; 2005; 52(1):46-59. PubMed ID: 15975832
[TBL] [Abstract][Full Text] [Related]
14. Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds.
Tao H; Santa Ana D; Guia A; Huang M; Ligutti J; Walker G; Sithiphong K; Chan F; Guoliang T; Zozulya Z; Saya S; Phimmachack R; Sie C; Yuan J; Wu L; Xu J; Ghetti A
Assay Drug Dev Technol; 2004 Oct; 2(5):497-506. PubMed ID: 15671647
[TBL] [Abstract][Full Text] [Related]
15. A history of the role of the hERG channel in cardiac risk assessment.
Rampe D; Brown AM
J Pharmacol Toxicol Methods; 2013; 68(1):13-22. PubMed ID: 23538024
[TBL] [Abstract][Full Text] [Related]
16. Development of a high-throughput electrophysiological assay for the human ether-à-go-go related potassium channel hERG.
Gillie DJ; Novick SJ; Donovan BT; Payne LA; Townsend C
J Pharmacol Toxicol Methods; 2013; 67(1):33-44. PubMed ID: 23103595
[TBL] [Abstract][Full Text] [Related]
17. Validation of a guinea pig Langendorff heart model for assessing potential cardiovascular liability of drug candidates.
Guo L; Dong Z; Guthrie H
J Pharmacol Toxicol Methods; 2009; 60(2):130-51. PubMed ID: 19616638
[TBL] [Abstract][Full Text] [Related]
18. Choice of cardiac tissue plays an important role in the evaluation of drug-induced prolongation of the QT interval in vitro in rabbit.
Lu HR; Vlaminckx E; Teisman A; Gallacher DJ
J Pharmacol Toxicol Methods; 2005; 52(1):90-105. PubMed ID: 15978848
[TBL] [Abstract][Full Text] [Related]
19. Acquired QT interval prolongation and HERG: implications for drug discovery and development.
Finlayson K; Witchel HJ; McCulloch J; Sharkey J
Eur J Pharmacol; 2004 Oct; 500(1-3):129-42. PubMed ID: 15464027
[TBL] [Abstract][Full Text] [Related]
20. Automated Patch-Clamp Methods for the hERG Cardiac Potassium Channel.
Houtmann S; Schombert B; Sanson C; Partiseti M; Bohme GA
Methods Mol Biol; 2017; 1641():187-199. PubMed ID: 28748465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
